Navigation Links
Three-Year Follow-Up Data Confirm Safety and Survival Benefit in Chinese Liver Failure Patients Treated With ELAD® Bioartificial Liver
Date:10/13/2010

SAN DIEGO, Oct. 13 /PRNewswire/ -- Vital Therapies, Inc., (VTI) today announced that a poster is being presented at the American Association for the Study of Liver Diseases (AASLD) meeting in Boston on Tuesday, November 2nd. It confirms that previously reported findings of improved transplant free survival (TFS) in Chinese subjects with acute-on-chronic liver failure (ACLF) treated with the ELAD® bioartificial liver support system are maintained for up to three years.

The poster is titled "3-year follow-up of acute-on-chronic liver failure (ACLF) subjects in randomized, controlled, multicenter trial of ELAD® bioartificial liver support system in 49 Chinese subjects reveals significant transplant-free survival (TFS) benefit." It is being presented by Dr. Michael Millis, Professor of Surgery, University of Chicago, and is coauthored by Drs. Zhongping Duan and Jing Zhang, Beijing You'an Hospital, and Shaojie Xin and Shaoli You, 302 Military Hospital, Beijing.

Previously, it was reported that 84-day follow-up of ACLF subjects enrolled at two liver treatment centers in China showed statistically significant improvements in TFS for ELAD treatment compared with standard of care (SOC). At least three years following enrollment, survivors were consented and underwent a cancer screen and physical exam in accord with a questionnaire.

Of 49 subjects enrolled, 84-day TFS was 21/32 (65.6%) in the ELAD group vs. 7/17 (41.1%) in controls. Three-year TFS was 14/32 (43.8%) in the ELAD group vs. 3/12 (25%) in controls. Of 84-day survivors, 2/21 (9.5%) ELAD and 2/7 (28.6%) controls died, 1/21 (4.8%) ELAD and 0/7 controls were transplanted and 4/21 (19.0%) ELAD and 2/7 (28.6%) controls were lost to follow-up. Survival analysis reveals a statistically significant improvement in TFS (p=0.045, log-rank analysis) for the ELAD treated subjects compared with SOC. Median survival of controls was 37 days, whereas median survival of ELAD treated subjec
'/>"/>

SOURCE Vital Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
3. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
4. MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices
5. Bacterin International Secures Three-Year Agreement to Distribute Biologic Products to Broadlanes Network of Over 6,000 Medical Facilities
6. Comfort Medical Supply, LLC Ranks No. 461 on the 2010 Inc. 500 with Three-Year Sales Growth of 649%
7. Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600%
8. Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinsons Disease
9. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
10. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
11. Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015 The Assistance Fund announces the ... provides financial assistance for copay to individuals diagnosed with ... the addition of the Melanoma Copay Assistance Program to ... , executive director. "With each additional program we are ... world where no one is denied access to medications ...
(Date:5/22/2015)... 22, 2015  The U.S. Food and Drug ... the first biosimilar product approved in ... growth in the contract manufacturing organization (CMO) industry, ... is geared to the production of small-molecular drugs ... products. The healthcare market research publisher,s report, ...
(Date:5/22/2015)... , May 20, 2015 Research and ... the "Guide to Prepare Application Dossiers for ... (2014 Edition) " report to their offering. ... one of segment market of the most growth ... medical device manufacturers and producers to penetrate such ...
Breaking Medicine Technology:The Assistance Fund Adds Melanoma Assistance Program 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3
(Date:5/22/2015)... 2015 Family, friends, students, colleagues, mentors ... oncologist, Dr. LaSalle D. Leffall, on Monday, May 18, ... after Grand Rounds in the hospital’s Tower Auditorium. Leffall’s ... the auditorium, trying to keep the secret. “I’d like ... sees me, he’ll know something is up,” she said. ...
(Date:5/22/2015)... Knoxville, TN (PRWEB) May 22, 2015 Power ... Andrew Drobeck for the 2015 race season. Drobeck is in ... also serves as a firefighter with the Missoula Fire Department ... and became a Pro in 2014. During his career, he ... as a Pro, Drobeck recorded top 10 finishes in all ...
(Date:5/22/2015)... Gateway Building Concepts is experienced with all forms of ... in include decks, additions, kitchen remodeling, interior renovations, exterior ... , The redesigned logo is a fresh modern ... includes two geometrical lines that represent the engineering aspect ... used with many things associated with the company. The ...
(Date:5/22/2015)... 22, 2015 DMG Productions announces the ... to broadcast on Friday, May 29, 2015 at 7:30 ... , In this episode Innovations will explore Interstate Restoration, ... business quickly through disaster recovery and restoration. , Additionally, ... works collaboratively to develop and deliver training and education ...
(Date:5/22/2015)... Co founders Greenlee and James Chapko, DDS ... dentists to immediately deliver fully integrated dental implant services to ... the medical surgeon. , The Center, whose name is ... dentists from placing dental implants. These 6 roadblocks can ... the surgical placement of dental implants into his or her ...
Breaking Medicine News(10 mins):Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:New Episode of Innovations Airing Friday, May 29, 2015 Via Discovery Channel 2Health News:First of Its Kind Dental Implant Training and Surgicenter to Open in June 2
... , Researchers have undertaken a large-scale investigation ... protein (APP), a protein centrally associated with Alzheimer,s ... is the extracellular accumulation of amyloid plaques in ... cleavage of APP, which generates short, sticky fragments ...
... have identified a number of new genes that can ... that hopefully might be used to treat the disease ... These unique findings are being published in three ... Genetics. , SLE (systemic lupus erythematosus) is a so-called ...
... of Neurosciences at Mount Sinai School of Medicine have ... novel targeted gene therapy. In an effort to find ... Mount Sinai developed a gene therapy technique that simulates ... study Sensory neuron targeting by self-complementary AAV8 via lumbar ...
... 2007 An international research team, led by a ... (CHUM), has identified new therapeutic targets for the treatment ... Nature Immunology, the team provides fresh answers concerning the ... MS, a chronic autoimmune disease of the nervous system ...
... study says , , TUESDAY, Jan. 22 (HealthDay News) -- ,A ... liver cancer also increases the risk of developing high blood ... carefully monitored and treated, said the authors of a study ... Oncology . , Nexavar is an anti-angiogenesis drug, meaning it ...
... A new study reveals significant racial and ethnic differences ... sarcomas, a rare but dangerous cancer that begins in ... the body. The findings are published in the March ... the American Cancer Society. , While racial and ethnic ...
Cached Medicine News:Health News:Story ideas from Molecular and Cellular Proteomics 2Health News:Researchers find relief for chronic pain 2Health News:New therapeutic target for treatment of multiple sclerosis 2Health News:Liver Cancer Drug Raises Blood Pressure 2Health News:Disparities among patients with extremity soft-tissue sarcomas 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: